ESLA — Estrella Immunopharma, Inc.

Healthcare • Biotechnology

$2.28
-0.05 (—%)

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Company

Ticker
ESLA
Exchange
Sector
Healthcare
Industry
Biotechnology
Country
US
CEO
Cheng Liu
Employees
Website
www.estrellabio.com

Price

Showing 3M history. Source: FMP “historical price full”.

Prev Close
$2.33
Day High
$2.55
Day Low
$2.16
52w High
$2.55
52w Low
$0.63
Volume
293,886
Avg Volume
Beta
0.393

Key Metrics

Market Cap
84.5M
P/E
P/B
P/S
EV/EBITDA
ROE
Net Margin
Div Yield
FCF/Share

* TTM/most recent where available